ARS Pharmaceuticals, Inc (SPRY)
Healthcare
Biotechnology
—
5.10 $
-8.9%
vs. previous close
Closing price · As of: 31. Jul 2026
ARS Pharmaceuticals, Inc (SPRY) by the numbers: income statement, balance sheet and cash flow, by year or by quarter. In the most recent period (2025), "Operating Cash Flow" came in at -171 million USD. Tick rows to compare them in a chart.
All figures in millions of USD.
| Tick rows to compare them in a chart (up to 4) | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| -17 | -19 | 9.1 | -18 | -40 | -59 | 14 | -171 | |
| 1.4 | 1.5 | 0.0 | 0.2 | 0.3 | 0.1 | -7.2 | 1.4 | |
| – | – | 3.5 | 2.8 | 5.8 | 9.2 | 15 | 22 | |
| – | – | 3.7 | 3.0 | 7.0 | – | – | – | |
| -0.4 | 3.3 | 6.5 | -0.4 | -13 | -7.3 | -1.8 | -20 | |
| 0.4 | 0.1 | 0.9 | 0.1 | 0.2 | 0.2 | 0.6 | 0.3 | |
| -0.4 | -0.1 | -0.9 | -0.1 | -0.2 | -87 | -106 | 57 | |
| – | – | – | – | 0.6 | – | – | – | |
| – | – | 5.0 | -1.8 | -8.7 | 0.0 | 0.0 | 96 | |
| 19 | 8.6 | 5.1 | 53 | 191 | 6.9 | 72 | 105 | |
| 2.1 | -10 | 14 | 36 | 150 | -140 | -20 | -9.5 | |
| -17 | -19 | 8.2 | -18 | -40 | -59 | 13 | -171 |
Data as of: July 31, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.